ETHZilla(NASDAQ) ETHZ

Market Cap$75.69M

Since IPO (2017)-100%

5 Year-100%

1 Year-82%

1 Month-1%

$5.56

-2.97%

-0.17Today

ETHZilla last closing stock price
Metric	Price	Date
Last close	USD 5.54	2026-07-27

ETHZilla stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-8.58%	USD 6.06	2026-07-20
1 month	-0.72%	USD 5.58	2026-06-26
3 month	+7.78%	USD 5.14	2026-04-28
Year to date	+13.06%	USD 4.90	2025-12-31
1 year	-81.53%	USD 30.00	2025-07-25
3 year	-96.81%	USD 173.85	2023-07-28
5 year	-99.98%	USD 26,448.00	2021-07-28
Since inception	-99.98%	USD 36,859.99	2017-06-27

ETHZilla Financials at a Glance

Market Cap

$75.69M

Revenue (TTM)

$2.44B

Net Income (TTM)

-$450.59B

EPS (TTM)

-$35.46

P/E Ratio

-0.16

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$5.56

Volume

183,128.65

Open

$5.99

Price

$5.56

Volume

183,128.65

Open

$5.99

Previous Close

$5.54

Daily Range

$5.52 - $6.01

52-Week Range

$1.76 - $174.60

Estimated Earnings Date

Mar 31, 2026

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$5.56

Volume

183,128.65

Open

$5.99

Previous Close

$5.54

Daily Range

$5.52 - $6.01

52-Week Range

$1.76 - $174.60

Estimated Earnings Date

Mar 31, 2026

ETHZ News

Why 180 Life Sciences Stock Is Falling Today

Cory RenauerAug 19, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ETHZilla

180 Life Sciences Corp. is a biotechnology company focused on researching and developing innovative therapies for inflammatory diseases. The company targets significant unmet medical needs with its main focus on anti-TNF (tumor necrosis factor) biologics, addressing conditions like Dupuytren’s contracture and frozen shoulder. Led by a team with extensive pharmaceutical expertise, 180 Life Sciences aims to advance its pipeline through clinical trials, strategic partnerships, and licensing opportunities.

Products and Services

Anti-TNF biologics targeting inflammatory diseases

Research and development of therapies for Dupuytren’s contracture

Treatment development for frozen shoulder

Expanding pipeline of novel therapeutics

What Makes 180 Life Sciences Corp. Special

180 Life Sciences Corp. distinguishes itself through its focus on unique anti-TNF biologics, which target specific inflammatory pathways. This innovative approach could reshape treatment paradigms in its target conditions, setting it apart in the biotech industry. Its experienced leadership enhances its capabilities in development and commercialization strategies.

Five Things You Need to Know

The company focuses on unmet medical needs in the inflammatory disease sector.

Its leadership comprises seasoned pharmaceutical veterans.

The anti-TNF biologics target specific inflammatory pathways, unlike traditional therapies.

Strategic growth involves clinical trials and development partnerships.

180 Life Sciences is built on leveraging intellectual property for licensing opportunities.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

McAndrew A. Rudisill

Website

www.ethzilla.com

Headquarters

Palo Alto, CA 94306, US

ETHZ Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-2622.51%

Net Income Margin

-5489.52%

Return on Equity

-240.64%

Return on Capital

-47.60%

Return on Assets

-248.71%

Earnings Yield

-6.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$75.69M

Shares Outstanding

13.21M

Volume

183.13K

Avg. Volume

386.00K

Financials (TTM)

Gross Profit

$6.50M

Operating Income

-$235.71M

EBITDA

-$9.83B

Operating Cash Flow

-$25.31B

Capital Expenditure

-$16.81M

Free Cash Flow

-$25.33B

Cash & ST Invst.

$65.91M

Total Debt

$251.00K

ETHZilla Performance Analysis

ETHZilla annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 6,547,000	N/A

ETHZilla sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	59192.0%
Q1	2026-03-31	-99.9%

ETHZilla annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3,871.82	57.2%
2023	2023-12-31	USD -525.87	-86.4%
2024	2024-12-31	USD -154.91	-70.5%
2025	2025-12-31	USD -55.18	-64.4%

ETHZilla sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	54.9%
Q3	2025-09-30	-477.8%
Q4	2025-12-31	-68943.0%
Q1	2026-03-31	100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$2.86M

N/A

Gross Profit

$2.39M

N/A

Gross Margin

83.46%

N/A

Market Cap

$75.69M

N/A

Market Cap/Employee

$18.92M

N/A

Employees

N/A

Net Income

-$76.26M

-3118.9%

EBITDA

-$4.16M

-75.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$65.91M

+1669.5%

Total Debt

$251.00K

+65.3%

Accounts Receivable

$11.83M

+118360.3%

Inventory

$0.00

N/A

Long Term Debt

$25.95M

+757564.2%

Short Term Debt

$1.15M

+677.7%

Return on Assets

-2.49%

N/A

Return on Invested Capital

-1.27%

N/A

Free Cash Flow

-$37.09M

-4244.3%

Operating Cash Flow

-$20.28M

-2274.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GECCGreat Elm Capital Corp.

GECCGreat Elm Capital Corp.$5.14-1.53%

BDCIUBTC Development Corp. Unit

BDCIUBTC Development Corp. Unit$10.20+0.89%

SVACSpring Valley Acquisition Corp. III Class A Ordinary Shares

SVACSpring Valley Acquisition Corp. III Class A Ordinary Shares$9.12+0.00%

EFTYEtoiles Capital Group Co., Ltd. Class A Ordinary Shares

EFTYEtoiles Capital Group Co., Ltd. Class A Ordinary Shares$15.02+0.00%

LWACLightWave Acquisition Corp.

LWACLightWave Acquisition Corp.$10.26+0.29%

PLTSPlatinum Analytics Cayman Limited Class A Ordinary Shares

PLTSPlatinum Analytics Cayman Limited Class A Ordinary Shares$17.50+0.00%

PACHPioneer Acquisition I Corp

PACHPioneer Acquisition I Corp$10.27+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

BMNRBitmine Immersion Technologies

BMNRBitmine Immersion Technologies$17.92+0.13%

Questions About ETHZ

What is the current price of ETHZilla?

ETHZilla is trading at $5.54 per share.

What is the 52-week range for ETHZilla?

Over the past 52 weeks, ETHZilla has traded between $1.76 and $174.60.

How much debt does ETHZilla have?

As of the most recent reporting period, ETHZilla reported total debt of $27.10M.

How much cash does ETHZilla have on hand?

ETHZilla reported $65.91M in cash and cash equivalents in its most recent financial results.

What is ETHZilla’s dividend yield?

ETHZilla does not currently have a dividend yield.

ETHZilla(NASDAQ) ETHZ

ETHZilla Financials at a Glance

ETHZ News

Why 180 Life Sciences Stock Is Falling Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ETHZilla

Products and Services

What Makes 180 Life Sciences Corp. Special

Five Things You Need to Know

ETHZ Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ETHZilla Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ETHZ

What is the current price of ETHZilla?

What is the 52-week range for ETHZilla?

How much debt does ETHZilla have?

How much cash does ETHZilla have on hand?

What is ETHZilla’s dividend yield?

Premium Investing Services